Close menu




December 30th, 2020 | 09:29 CET

Everfuel, Q&M Dental Group, SAP - Focus on change!

  • Investments
Photo credits: pixabay.com

The year is drawing to a close. It has been an exciting year for the capital markets due to the Corona pandemic. In addition to reaching new highs at Dow, DAX & Co., the boom in IPOs, especially in the USA, was another surprise. The situation in the real economy is different, though. While Europe, South America and the United States are still suffering from the lockdowns, the Asian economies are recovering far faster than expected.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: SG2E73981531 , DK0061414711 , DE0007164600

Table of contents:


    New lifestyle

    Without question, Asia has come through the Corona pandemic best so far. Economies, especially in Southeast Asia, have been growing rapidly for years, as have employee wages. As a result, the new, more expensive standard of living of the emerging middle class boosts consumption. Besides the strong demand for foreign travel and consumer goods, Asians are particularly keen to invest in health and beauty. In the fast-growing dental aesthetics and dentistry market, Singapore-based Q&M Dental Group is a major beneficiary of this trend.

    Founded in 1996, the Company is a leading private dental group in Asia and the largest private dental service provider in Singapore. The group operates 114 dental offices, 5 medical clinics, 3 dental supplies and equipment distribution companies in Singapore, Malaysia and China. With the help of 230 dentists and over 400 employees, Q&M Dental Group serves more than 600,000 patients.

    Research with artificial intelligence

    Already well advanced in the area of research is the development of a platform with the help of artificial intelligence. The Q&M Dental Group is cooperating with AI Singapore and a team from the International Medical University in Malaysia. The clinical data that Q&M has collected over the years will be combined with dentistry's latest research on the platform. As a result, the patient's underlying disease can be identified quickly, and the most appropriate treatment method suggested.

    Further growth as a goal

    The pre-pandemic plan was to open 10 more clinics in 2020. In addition, expansion into Malaysia and China was to be accelerated. In contrast to Germany, in Asia, dental treatments were also suspended in the event of a lockdown, and the Company had to act without further ado. It acquired a stake in Acumen Diagnostics, a manufacturer of test kits for Covid-19. The high demand was thus able to compensate for part of the shortfall but is only to play a minor supporting role in the business strategy in the future.

    The Q&M Dental Group share has recently been listed on the primary stock exchange in Singapore and Germany. The stock market value is currently EUR 221 million. The strongly growing dental market in Asia and the outstanding position of the group certainly offer fantasy.

    With the subsidiary on the trading floor

    In the summer, news leaked out that SAP is planning to venture onto the stock market with its subsidiary Qualtrics. Qualtrics offers a software platform with which companies can collect data from customers, traders, and employees to analyze and process it in real-time. The stock market debut can happen quickly; here's how the debut's first details are coming from the Company.

    "XM" is the abbreviation under which the market research Company is to be listed on the USA's Nasdaq technology exchange. Although the number of shares and the exact date are unknown, Qualtrics shares are to be sold for up to USD 24 under the aegis of investment banks Morgan Stanley and JP Morgan.

    SAP retains dominance

    The purchase of the analysis Company, which was completed only two years ago, was extremely lucrative. The Walldorf-based Company paid a mere USD 8.0 billion. Looking at the peer group, a doubling could well be on the books. To profit further from the technology, SAP intends to remain a majority shareholder in Qualtrics to integrate the subsidiary's features into existing SAP products.

    The heavily beleaguered SAP shareholders received the news exceptionally positively. As a result, the share price jumped above the resistance level of EUR 106.00 and is working to close the share price gap at just under EUR 123.00 that opened since the horror figures.

    Hand in Hand

    One step further in the development of its subsidiary is the hydrogen specialist Nel ASA. The Norwegians own just under 17% of the Danish spin-off Everfuel. However, both on the stock market and fundamentally, the Company's development is going like clockwork. We already reported the tender success for a hydrogen site in Oslo and the memorandum of understanding with Green Hydrogen Hub Denmark to build a 350 MW electrolysis plant, a 200,000 MWh hydrogen facility and another energy storage facility.

    The mother helps

    Now Everfuel announces another deal engineered by its parent Nel ASA. The Danes are acquiring 100% of Danish Hydrogen Fuel A/S shares from former owners NelHydrogen A/S, gas producers Strandmøllen A/S and the Danish fuel company OKA. Danish Hydrogen Fuel owns and operates 4 introduced hydrogen refueling stations near the Danish cities of Korsør, Kolding, Esbjerg and Aarhus.

    On the stock market, Everfuel is being celebrated as if there would be no more shares tomorrow. Since the IPO in October, the share price has risen from NOK 22 to NOK 121.20! The stock market value amounts to EUR 665.9 million. Very stately, for the still relatively small, contemplative enterprise. Investors should, however, be extremely cautious due to the low free float of a maximum of 5%.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read